Will pindolol augment the response to a serotonin reuptake inhibitor in obsessive-compulsive disorder?
Koran
L M
LM
Mueller
K
K
Maloney
A
A
D015057:1-Naphthylamine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use*; D002997:Clomipramine / Q000627:therapeutic use; D004357:Drug Synergism; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy*; D010869:Pindolol / Q000627:therapeutic use*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D020280:Sertraline
D015057:1-Naphthylamine; D000319:Adrenergic beta-Antagonists; D000928:Antidepressive Agents; D002997:Clomipramine; D005473:Fluoxetine; D010869:Pindolol; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline